Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NXTC
- Price
- 5.64
- Stock movement down
- -0.24 (-0.39%)
- Company name
- NextCure Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 164.10M
- Ent value
- 151.15M
- Price/Sales
- 26.11
- Price/Book
- 2.17
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -0.16%
- 1 year return
- -97.82%
- 3 year return
- -80.93%
- 5 year return
- -67.04%
- 10 year return
- -
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NXTC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 26.11 |
| Price to Book | 2.17 |
| EV to Sales | 24.05 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.68M |
| EPS (TTM) | -25.10 |
| FCF per share (TTM) | -19.31 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.28M |
| Gross profit (TTM) | 3.82M |
| Operating income (TTM) | -60.54M |
| Net income (TTM) | -58.52M |
| EPS (TTM) | -25.10 |
| EPS (1y forward) | -12.08 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 60.77% |
| Operating margin (TTM) | -963.41% |
| Profit margin (TTM) | -931.22% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 27.70M |
| Net receivables | 0.00 |
| Total current assets | 78.69M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 9.58M |
| Total assets | 90.34M |
| Accounts payable | 3.61M |
| Short/Current long term debt | 5.39M |
| Total current liabilities | 8.67M |
| Total liabilities | 14.75M |
| Shareholder's equity | 75.59M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -44.51M |
| Capital expenditures (TTM) | 521.00K |
| Free cash flow (TTM) | -45.03M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -77.41% |
| Return on Assets | -64.77% |
| Return on Invested Capital | -77.41% |
| Cash Return on Invested Capital | -59.57% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 59.76 |
| Daily high | 63.41 |
| Daily low | 59.76 |
| Daily Volume | 1K |
| All-time high | 159356.16 |
| 1y analyst estimate | 17.50 |
| Beta | 1.26 |
| EPS (TTM) | -25.10 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 30 Oct 2025 |
Downside potential
Loading...
Downside potential data
| NXTC | S&P500 | |
| Current price drop from All-time high | -99.96% | -1.46% |
| Highest price drop | -99.96% | -56.47% |
| Date of highest drop | 11 Jul 2025 | 9 Mar 2009 |
| Avg drop from high | -85.01% | -10.99% |
| Avg time to new high | 66 days | 12 days |
| Max time to new high | 1456 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
164.10M
Marketcap category
Small-cap
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Employees
43
Website
Investor relations
-
SEC filings
CEO
Michael S. Richman
Country
USA
City
Beltsville
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page